David Steinberg
Stock Analyst at Jefferies
(2.93)
# 1,668
Out of 5,046 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $7.02 | +13.96% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $20.74 | +203.76% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $55.13 | -27.44% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $137.54 | +36.69% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $11.66 | -31.39% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $4.15 | +381.93% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $7.02
Upside: +13.96%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $20.74
Upside: +203.76%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $55.13
Upside: -27.44%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $137.54
Upside: +36.69%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $11.66
Upside: -31.39%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $4.15
Upside: +381.93%